A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells.

While Polo-like kinase 1 (PLK1) inhibitors have shown promise in clinical settings for treating triple-negative breast cancer tumors and other solid tumors, they are limited by their ability to bind non-selectively to the ATP kinase domain. Therefore, we sought to develop a PLK1 allosteric inhibitor targeting the PLK1 T-loop (a switch responsible for activation) and evaluate its effects in triple-negative breast cancer cells. A novel compound, RK-10, was developed based on an in silico model, and its effects on specificity, viability, migration, and cell cycle regulation in MCF-10A and MDA-MB 231 cells were evaluated.

Influence of temperature on the thirty-day chemical stability of extemporaneously prepared dexamethasone paste.

Dexamethasone, a high-potency synthetic glucocorticoid, is often used to treat various immunological and inflammatory conditions. Commercial preparations of dexamethasone facilitate administration to human patients. Veterinary use of dexamethasone may be complicated by the unavailability of commercial dosage forms.

Interfacially assembled carbohydrate nanocapsules: a hydrophilic macromolecule delivery platform.

A prospective approach was used to synthesize carbohydrate nanocapsules with a macromolecule payload and suitable interfacial properties for in vivo systemic circulation. Spatially directed carbohydrate assembly and polymerization resulted in structured hydrophilic vesicles with diameters of 200-300 nm. Mononucleated dispersions with monodisperse distributions were demonstrated in aqueous vehicles.